

# ACTRIMS Forum 2023

## CE Information

### WELCOME

The Americas Committee for Treatment and Research in Multiple Sclerosis is pleased to welcome you to the seventh annual ACTRIMS Forum 2023! The ACTRIMS Forum 2023, themed *MS: Going Viral*, will be held in San Diego, California on February 23 – 25, 2023.

### EDUCATIONAL CREDITS

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Interstate Postgraduate Medical Association (IPMA) and ACTRIMS. The IPMA is accredited by the ACCME to provide continuing medical education for physicians.

The Interstate Postgraduate Medical Association designates this live activity for a maximum of 15 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the [ABMS Continuing Certification Directory](#), **ACTRIMS Forum 2023** has met the requirements as a **Lifelong Learning CME Activity** (apply toward general CME requirement) for the following ABMS Member Boards:

#### **ABMS Lifelong Learning CME Activity**

Psychiatry and Neurology

[ABMS Continuing Certification Diplomate Survey](#)

If you require clarification of these statements, please contact the CME Office:

Interstate Postgraduate Medical Association (IPMA)

Heidi Ness, Director of Education & Accreditation

Email: [hness@ipmameded.org](mailto:hness@ipmameded.org)

Phone: (608) 592-1622

For information on how this activity fits in the **Royal College Maintenance of Certification (MOC) Program**, please visit the [Royal College's](#) website. For more personalized support, please contact the [Royal College Services Centre](#) (1-800-461-9598) or your local [CPD Educator](#).

### COMMERCIAL SUPPORT

The ACTRIMS Forum 2023 is supported in part by unrestricted educational grants from the following commercial entities:

- Biogen

### DISCLOSURE STATEMENTS

As a provider dedicated to independent education and accredited by the ACCME, IPMA must ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All individuals with potential to influence the content of this program have disclosed all financial relationships that have occurred in the past 24 months with ineligible companies. The disclosures have been reviewed according to policy and these declarations are listed below. All individuals with potential conflicts have been contacted as needed by IPMA staff, and issues of conflict have been discussed, managed, and mitigated. All presentations were reviewed by an independent clinician with no disclosed relevant financial relationships for the purpose of resolution of any identified conflict of interest and a determination of evidence-based and fair balance.

Additionally, all faculty, reviewers, and planners have been asked to disclose to learners any discussion of off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United

States and investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Name	Role	Disclosure
Martina Absinta, MD, PhD	Abstract Reviewer	Consultant: ABATA Therapeutics, GSK
Dritan Agalliu, PhD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Omar Al-Louzi, MD	Faculty	No relevant financial relationships with ineligible companies to disclose
Jorge I Alvarez, PhD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Lilyana Amezcua, MD, MS, FAAN	Faculty	Advisory Board: EMD Serono; Advisory Board & Research: Genentech, Biogen; Research: Sanofi/Genzyme
Jack Antel, MD	Planner, Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Nathalie Arbour, PhD	Abstract Reviewer	Research: Merck-EMD
Navid Manouchehri Ardestani, MD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Douglas Arnold, MD	Abstract Reviewer	Consultant: Biogen, Celgene, Frequency Therapeutics, Genentech, Merck, Novartis
Christina Azevedo, MD, MPH	Abstract Reviewer	Advisory Board & Consultant: Genentech; Advisory Board: Sanofi Genzyme, TG Therapeutics, Horizon Therapeutics
Francesca Bagnato, MS, PhD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Laura Balcer, MD, MSCE	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Sergio Baranzini, MD	Planner, Abstract Reviewer, Faculty	Co-Founder: Mate Bioservices
Amit Bar-Or, MD	Planner, Abstract Reviewer	Advisory Board & Consultant: Accure, Atara Biotherapeutics, Biogen, BMS/Celgene/Receptos, GlaxoSmithKline, Gossamer, Janssen/Actelion, Medimmune, Merck/EMD Serono, Novartis, Roche/Genentech, Sanofi-Genzyme; Research: Biogen Idec, Roche/Genentech, Merck/EMD Serono and Novartis.
Eduardo Beltrán, PhD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Jeffrey Bennett, MD, PhD	Abstract Reviewer	Advisory Board, Consultant & Research: Alexion; Consultant: Biogen, Antigenomycs, Reistone Bio, Clene Nanomedicine, Mitsubishi-Tanabe; Advisory Board & Consultant: Roche-Genentech-Chugai, Viela Bio-Horizon Therapeutics; Advisory Board: TG Therapeutics; Speakers Bureau: EMD Serono
Etty (Tika) Benveniste, PhD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Robert Bermel, MD	Abstract Reviewer	Consultant: Biogen, EMD Serono, Novartis, Genentech/Roche, Sanofi/Genzyme, Astra-Zeneca, LabCorp, Horizon
Bibi Bielekova, MD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Dennis Bourdette	Abstract Reviewer	
Riley Bove, MD	Abstract Reviewer	Advisory Board: Alexion; Research: Biogen; Consultant: EMD Serono, Horizon, Jansen, Novartis
James Bowen, MD	Abstract Reviewer	Advisory Board, Consultant, Research & Speakers Bureau: Biogen IDEC, Bristol Myers Squibb, Genentech, Novartis; Advisory Board & Research: TG Therapeutics; Research: EMD Serono, Roche, Sanofi
Tiffany Braley, MD	Planner	No relevant financial relationships with ineligible companies to disclose
Alexander Brandt, MD	Faculty	Advisory Board & Investment: Motognosis GmbH, Nocturne GmbH

Jodie Burton, ME, MSc, FRCPC	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Peter A Calabresi, MD	Abstract Reviewer, Faculty	Advisory Board: Idorsia; Advisory Board: Lilly, Biogen
Claudia Cantoni, PhD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Alise Carlson, MD	Faculty	No relevant financial relationships with ineligible companies to disclose
Brianna Carney	Faculty	No relevant financial relationships with ineligible companies to disclose
Anibal Chertcoff, MD	Faculty	No relevant financial relationships with ineligible companies to disclose
Tanuja Chitnis, MD	Planner, Abstract Reviewer	Advisory Board, Consultant & Research: Novartis; Advisory Board & Research: Genentech; Research: Bristol Myers Squibb
Jeffrey Cohen, MD	Planner, Abstract Reviewer	Research: Glaxo Smith Kline, ADMA Biologics; Consultant: Biogen, Convelo, EMD Serono, Gossamer Bio, Mylan, PSI
Jorge Correale, MD	Faculty	Advisory Board, Consultant, Research: Merck; Advisory Board, Consultant, Speakers Board: Biogen; Research & Speakers Bureau: Roche, Sanofi Genzyme; Advisory Board, Consultant, Research & Speakers Bureau: Novartis
Irene Cortese, MD	Abstract Reviewer, Faculty	Investment: Keires, AG, Nouscom, AG, PDC*line Pharma
Marianna Cortese, MD, PhD	Abstract Reviewer, Faculty	Speakers Bureau: Roche
Fiona Costello, MD, FRCPC	Planner, Abstract Reviewer	Speakers Bureau: Alexion, Accure Therapeutics, Novartis, Frequency Therapeutics
Bruce Cree, MD, PhD, MAS	Abstract Reviewer	Consultant: Alexion, Atara, Autobahn, Avotres, Biogen, EMD Serono, Gossamer Bio, Hexal/Sandoz, Horizon, Neuron23, Novartis, Sanofi, and TG Therapeutics
Gary Cutter, PhD	Abstract Reviewer	Data and Safety Monitoring Boards: Applied Therapeutics, AI therapeutics, AMO Pharma, Astra-Zeneca, Avexis Pharmaceuticals, Biolinerx, Brainstorm Cell Therapeutics, Bristol Meyers Squibb/Celgene, CSL Behring, Galmed Pharmaceuticals, Green Valley Pharma, Horizon Pharmaceuticals, Immunic, Karuna Therapeutics, Mapi Pharmaceuticals LTD, Merck, Mitsubishi Tanabe Pharma Holdings, Opko Biologics, Prothena Biosciences, Novartis, Regeneron, Sanofi-Aventis, Reata Pharmaceuticals, Visioneering Technologies, Inc.
Philip De Jager, MD	Planner	Advisory Board & Research: Biogen, Roche; Research: Puretech
Gustavo Della Flora Nunes, PhD		Research: Autobahn Therapeutics
Tara M. DeSilva, PhD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Haritha Desu, PhD	Faculty	No relevant financial relationships with ineligible companies to disclose
Suhayl Dhib-Jalbut, MD	Planner, Faculty	Research: Biogen
Bonnie Dittel, PhD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Michael G. Dwyer, PhD	Faculty	Research: MAPI Pharma, Novartis; Research & Speakers Bureau: Bristol Myers Squibb; Speakers Bureau: Biogen
Diego Espinoza	Faculty	
Lisa Eunyoung Lee, MSc		No relevant financial relationships with ineligible companies to disclose
Giulia Fadda, MD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Eoin Flanagan	Faculty	
Mark Freedman, MD	Planner, Abstract Reviewer	Advisory Board & Consultant: Atara Biotherapeutics, Biogen Idec, Janssen, Bayer Healthcare; Advisory Board, Consultant & Speakers Bureau: EMD Serono, Alexion

Leorah Freeman, MD, PhD	Faculty	Advisory Board & Research: Genentech; Consultant: Novartis; Advisory Board, Consultant & Research: EMD Serono; Advisory Board: TG Therapeutics; Advisory Board, Consultant & Speakers Bureau: Bristol Myers Squibb
María Inés Gaitán, MD	Faculty	No relevant financial relationships with ineligible companies to disclose
Lorna Galleguillos, MD	Faculty	Advisory Board, Consultant & Speakers Bureau: Biogen Idec, Merck, Sanofi Genzyme, Roche, Bristol Myers Squibb, Sanofi Genzyme
Thomas Garton	Faculty	No relevant financial relationships with ineligible companies to disclose
Susan A. Gauthier, DO, MPH	Abstract Reviewer, Faculty	Advisory Board: Genentech
Jennifer Gommerman, PhD	Abstract Reviewer	Research: Novartis, Merck, Roche
Jennifer Graves, MD PhD, MAS	Faculty	Advisory Board: Bayer, Genentech
Anne Haney Cross, MD	Planner, Faculty	Consultant: Biogen; Advisory Board & Consultant: Novartis; Advisory Board, Consultant & Research: EMD Serono; Consultant & Research: Genentech; Advisory Board: Horizon Therapeutics, Janssen (J&J), Advisory Board & Consultant: Bristol Myers Squibb; Advisory Board: TG Therapeutics
Samantha Hao	Faculty	No relevant financial relationships with ineligible companies to disclose
Christopher Hemond, MD	Abstract Reviewer	Consultant: VIVIO Health
Roland Henry	Abstract Reviewer	
Emily A. Holt	Faculty	No relevant financial relationships with ineligible companies to disclose
Marc Horwitz, PhD	Faculty	No relevant financial relationships with ineligible companies to disclose
Steven Jacobson, PhD	Abstract Reviewer, Faculty	No relevant financial relationships with ineligible companies to disclose
Rajiv Jain, PhD	Faculty	Research Fellowship: Roche
Marwa Kaisey, MD	Faculty	Advisory Board: Novartis; Speakers Bureau: Biogen; Advisory Board & Speakers Bureau: Genentech
Emily Kamma, BSc	Faculty	No relevant financial relationships with ineligible companies to disclose
Orhun Kantarci	Abstract Reviewer	
Soheila Karimi, PhD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Deepak Kaushik, MD	Faculty	No relevant financial relationships with ineligible companies to disclose
B. Mark Keegan, MD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Dorlan Kimbrough, MD	Faculty	No relevant financial relationships with ineligible companies to disclose
Elaine Kingwell, PhD	Faculty	No relevant financial relationships with ineligible companies to disclose
Eric Klawiter, MD	Abstract Reviewer	Consultant: OM1, Greenwich Biosciences; Advisory Board: Banner Life Science, TG Therapeutics; Advisory Board & Research: Genentech, Biogen
Shannon Kolind, PhD	Abstract Reviewer	Consultant & Research: Roche; Research: Biogen, Sanofi
Peter Kosa, PhD	Faculty	No relevant financial relationships with ineligible companies to disclose
Hedwich Kuipers, PhD	Faculty	No relevant financial relationships with ineligible companies to disclose
Amy Kunchok, MD	Abstract Reviewer	Advisory Board: Genentech, Horizon Therapeutics; Consultant: EMD Serono

Christine LeBrun Frenay, MD	Faculty	No relevant financial relationships with ineligible companies to disclose
Tom Lane	Abstract Reviewer	
Catherine Larochelle, MD, PhD	Planner, Abstract Reviewer	Advisory Board & Research: Celgene, Actelion, Alexion, Merck/EMD-Serono, Biogen, Novartis, Genzyme Sanofi, FindTx
Erin Longbrake, MD, PhD	Abstract Reviewer	Consultant & Research: Genentech; Consultant: EMD Serono, NGM Bio; Advisory Board: Bristol Myers Squibb, TG Therapeutics
Keri Lore	Planner	No relevant financial relationships with ineligible companies to disclose
Christopher Luzzio, MD	Content Review	No relevant financial relationships with ineligible companies to disclose
Caterina Mainero, MD, PhD	Abstract Reviewer	Research: Genentech
Sargis Manukyan	Faculty	No relevant financial relationships with ineligible companies to disclose
Yang Mao-Draayer, MD, PhD	Faculty	Advisory Board, Consultant & Research: Sanofi-Genzyme; Consultant & Research: Genentech; Research: Novartis; Consultant: Biogen, Janssen; Advisory Board: Horizon, EMD Serono
Ruth Ann Marrrie, MD, PhD	Abstract Reviewer	Research: Biogen Idec, Roche Canada
Veronique Miron, PhD	Abstract Reviewer	Research: Astex Pharmaceuticals; Consultant: Novartis
Scott Montgomery, MD	Faculty	Consultant: Merck
Craig Stephen Moore, PhD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Seyedamirhosein Motamedi, PhD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Kathleen Munger, MD	Faculty	Research: Anokion, Celgene, Corevitas, Novartis, F.Hoffman-La Roche, Genentech, EMD Serono; Fellowship Funding: Biogen
Robert T. Naismith, MD	Abstract Reviewer	Consultant: Abata Therapeutics, Alexion Pharmaceuticals, Biogen, Bristol Myers Squibb, Celltrion, Genentech, Genzyme, Janssen, GW Therapeutics, Horizon Therapeutics, Lundbeck, NervGen, TG Therapeutics
Heidi Ness	Planner	No relevant financial relationships with ineligible companies to disclose
Ahmed Obeidat	Abstract Reviewer	
Jiwon Oh, MD	Planner	Advisory Board & Consultant & Research: Biogen Idec, Roche, EMD-Serono Advisory Board & Consultant: Novartis, Sanofi-Genzyme, Bristol Myers Squibb, Alexion
Serhat V. Okar, MD	Faculty	No relevant financial relationships with ineligible companies to disclose
Daniel Ontaneda, MD, PhD	Planner, Abstract Reviewer	Consultant: Genentech, Novartis, Biogen
Kevin Patel, MD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Daniel Pelletier, MD	Abstract Reviewer	Consultant: Roche
Stanley Perlman, MD, PhD	Faculty	No relevant financial relationships with ineligible companies to disclose
Laura Piccio, MD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Sean J Pittock, MD	Abstract Reviewer	Advisory Board, Consultant & Research: Alexion, Horizon, Roche/Genentech, Roche, UCB; Consultant: Astellas; Advisory Board & Consultant: Arialys Therapeutics, Inc
David Pleasure, MD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Jason Plemel, PhD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Michelle Ploughman, PT, PhD	Faculty	Research: Helius Medical Technology

Christopher Power, MD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Alexandre Prat, MD, PhD, FRCPC	Planner	No relevant financial relationships with ineligible companies to disclose
Anne-Katrin Pröbstel, MD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Jacqueline Quandt, PhD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Manu Rangachari, PhD	Abstract Reviewer	Research: Remedy Pharmaceuticals
Daniel Reich, MD, PhD	Planner, Abstract Reviewer	Research: Abata Therapeutics, Sanofi-Genzyme
Claire Riley, MD	Abstract Reviewer, Faculty	Advisory Board & Consultant: Genentech; Consultant: Merck, TG Therapeutics; Advisory Board: Horizon Therapeutics, Janssen Global, Novartis
Victor M. Rivera, MD, FAAN	Faculty	Speakers Bureau: Roche Latin America
Maria Assunta Rocca, MD	Abstract Reviewer	Consultant: Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche; Speakers Bureau: Bayer, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Merck Healthcare Germany, Merck Serono SpA, Novartis, Roche, Teva
Andrew Russo	Faculty	No relevant financial relationships with ineligible companies to disclose
Shiv Saidha, MD	Planner, Faculty	Advisory Board & Research: Biogen, Novartis; Advisory Board, Consultant & Research: Genentech; Consultant & Research: Lapix therapeutics, JuneBrain; Advisory Board: TG Therapeutics; Research: Clene
Ilana Katz Sand, MD	Faculty	No relevant financial relationships with ineligible companies to disclose
Raphael Schneider, MD, PhD, FRCPC, CIP	Faculty	No relevant financial relationships with ineligible companies to disclose
Benjamin Segal, MD	Planner	Consultant: Banner Life Sciences, Eli Lilly
Russell Shinohara, PhD	Abstract Reviewer	Consultant: Octave Bioscience
Nancy L Sicotte, MD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
M. Mateo Paz Soldan, MD, PhD	Abstract Reviewer	Advisory Board: TG Therapeutics; Research: Novartis, Clene Nanomedicine
Andrew J Solomon, MD	Abstract Reviewer, Faculty	Speakers Bureau: EMD Serono; Advisory Board: Genentech, TG Therapeutics, Horizon Therapeutics : Fellowship funding: Biogen; Research: Bristol Meyers Squibb; Consultant: Octave Bioscience
Julio Sotelo Morales, MD	Faculty	No relevant financial relationships with ineligible companies to disclose
Lawrence Steinman	Faculty	Advisory Board: Bristol, Myers, Squibb; Board: BioAtla, 180 Life Sciences, Pasithea
Olaf Stuve, MD, PhD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Daiki Takewaki, MD	Faculty	No relevant financial relationships with ineligible companies to disclose
Helen Tremlett, PhD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Emily Viles-Monari, CAE	Planner	No relevant financial relationships with ineligible companies to disclose
Carlos A. Pardo-Villamizar, MD	Faculty	No relevant financial relationships with ineligible companies to disclose
Rhonda Voskuhl, MD	Planner, Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Sarita Walvekar	Faculty	No relevant financial relationships with ineligible companies to disclose

Emmanuelle Waubant, MD, PhD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Howard L. Weiner, MD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Eric Williamson, MD	Faculty	No relevant financial relationships with ineligible companies to disclose
Jerry S. Wolinsky, MD	Abstract Reviewer	Advisory Board: Avotres, EMD Serono; Consultant: Brainstorm Cell Therapeutics, Inmagene; Advisory Board & Consultant: Novartis/Sandoz, Roche/Genentech
Gregory Wu, MD, PhD	Abstract Reviewer	Research & Speaker Bureau: EMD Serono; Research: Biogen; Advisory Board: Sage, Sangamo
Zongqi Xia, MD, PhD	Faculty	Consultant & Research: Genentech / Roche; Research: Octave Bioscience
E. Ann Yeh, MD	Abstract Reviewer	Research & Speakers Bureau: Biogen; Advisory Board & Speakers Bureau: Roche; Research: Alexion; Advisory Board & Research: Horizon
V. Wee Yong, PhD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Scott Zamvil, MD	Planner	Advisory Board, Consultant & Speakers Bureau: Genzyme; Consultant: Teva; Advisory Board & Speakers Bureau: Alexion, Novartis; Advisory Board, Research & Speakers Bureau: Biogen; Advisory Board: VielaBio
Stephanie Zandee, MD	Faculty	No relevant financial relationships with ineligible companies to disclose
Anastasia Zekeridou, MD, PhD	Abstract Reviewer	Research: Roche/Genentech; Consultant: Alexion
Burcu Zeydan, MD	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose
Xia Zongqi	Abstract Reviewer	
Michelle Zuo	Abstract Reviewer	No relevant financial relationships with ineligible companies to disclose

### Privacy Policy

At IPMA, we care about providing you with tools and information to manage and protect your online privacy. IPMA retains records solely for keeping records in accordance with ACCME policies. We will not share your information with any other organizations. We will keep you informed of our CE activities. Please e-mail [cmehelp@ipmameded.org](mailto:cmehelp@ipmameded.org) if you do not want to receive any communications from us.